Changing How We Treat Relapsed/Refractory Hairy Cell Leukemia

Most patients with hairy cell leukemia (HCL) will eventually relapse following first-line purine analogue therapy and some will develop purine analogue&ndash refractory disease. Targeted therapies have improved outcomes for these patients with difficult-to-treat disease. Take this opportunity to deepen your understanding of current and evolving best practices for the treatment of patients with relapsed/refractory HCL.

Share

Program Content

Activities

R/R HCL Treatment
Changing How We Treat Relapsed/Refractory Hairy Cell Leukemia
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2019

Expires: April 22, 2020

Faculty

cover img faculity

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca